🇺🇸 FDA

Company profile · Sponsor

Keros

Keros Therapeutics

KROS · NYSE pharma LEXINGTON, MA, USA
Pipeline
3
Drugs
0
Patents
8

Quick answer

Keros (KROS) is a pharma company. headquartered in LEXINGTON, MA, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker KROS
Exchange NYSE
Company type pharma
Headquarters LEXINGTON, MA, USA
SEC CIK 0001664710

Pipeline (3)

Search pipeline →

  1. Dose A KER-012

    Keros

    Pulmonary Arterial Hypertension

    phase 2 mab completed

    1 trial

  2. KER-047

    Keros

    Iron Deficiency Anemia

    phase 2 small molecule terminated

    1 trial

  3. Placebo for KER-012, cibotercept

    Keros

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12404313

    GDNF fusion polypeptides and methods of use thereof

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12364737

    Activin receptor type IIA variants and methods of use thereof

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12350313

    Activin receptor type IIa variants and methods of use thereof

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12331124

    ALK2 antibodies and methods of use thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12269858

    Activin receptor type IIB variants and methods of use thereof

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12071438

    Crystal forms of an ALK2 inhibitor

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11912750

    GDNF fusion polypeptides and methods of use thereof

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11884715

    Activin receptor type IIB variants and methods of use thereof

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Keros?

Keros (KROS) is a pharma company. headquartered in LEXINGTON, MA, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Keros sponsor?

We track 3 ClinicalTrials.gov-linked programs for Keros, including Dose A KER-012 and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Keros company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.